Cardiorespiratory Comorbidity and Postoperative Complications Following Esophagectomy: a European Multicenter Cohort Study

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2019 Jun 12

PMID 31183640

Citations 31

Authors

F Klevebro

J A Elliott

A Slaman

B D Vermeulen

S Kamiya

C Rosman

S S Gisbertz

P R Boshier

J V Reynolds

I Rouvelas

G B Hanna

M I van Berge Henegouwen

S R Markar

Affiliations

Soon will be listed here.

Abstract

Background: The impact of cardiorespiratory comorbidity on operative outcomes after esophagectomy remains controversial. This study investigated the effect of cardiorespiratory comorbidity on postoperative complications for patients treated for esophageal or gastroesophageal junction cancer.

Patients And Methods: A European multicenter cohort study from five high-volume esophageal cancer centers including patients treated between 2010 and 2017 was conducted. The effect of cardiorespiratory comorbidity and respiratory function upon postoperative outcomes was assessed.

Results: In total 1590 patients from five centers were included; 274 (17.2%) had respiratory comorbidity, and 468 (29.4%) had cardiac comorbidity. Respiratory comorbidity was associated with increased risk of overall postoperative complications, anastomotic leak, pulmonary complications, pneumonia, increased Clavien-Dindo score, and critical care and hospital length of stay. After neoadjuvant chemoradiotherapy, respiratory comorbidity was associated with increased risk of anastomotic leak [odds ratio (OR) 1.83, 95% confidence interval (CI) 1.11-3.04], pneumonia (OR 1.65, 95% CI 1.10-2.47), and any pulmonary complication (OR 1.52, 95% CI 1.04-2.22), an effect which was not observed following neoadjuvant chemotherapy or surgery alone. Cardiac comorbidity was associated with increased risk of cardiovascular and pulmonary complications, respiratory failure, and Clavien-Dindo score ≥ IIIa. Among all patients, forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio > 70% was associated with reduced risk of overall postoperative complications, cardiovascular complications, atrial fibrillation, pulmonary complications, and pneumonia.

Conclusions: The results of this study suggest that cardiorespiratory comorbidity and impaired pulmonary function are associated with increased risk of postoperative complications after esophagectomy performed in high-volume European centers. Given the observed interaction with neoadjuvant approach, these data indicate a potentially modifiable index of perioperative risk.

Citing Articles

[Multimorbid patients in visceral surgery-Upper gastrointestinal tract].

Jung J, Bruns C Chirurgie (Heidelb). 2025; 96(2):89-94.

PMID: 39774998 DOI: 10.1007/s00104-024-02221-8.

Nomograms to predict tumor regression grade (TRG) and ypTNM staging in patients with locally advanced esophageal cancer receiving neoadjuvant therapy.

Qiu J, Zhang Z, Liu J, Zhao Y, Li Y, Tang Z World J Surg Oncol. 2024; 22(1):198.

PMID: 39068445 PMC: 11282666. DOI: 10.1186/s12957-024-03474-7.

Treatment of anastomotic leakage following Ivor Lewis esophagectomy-10 year experience from a Nordic center.

Hauge T, Dretvik T, Johnson E, Mala T Dis Esophagus. 2024; 37(9).

PMID: 38745429 PMC: 11360862. DOI: 10.1093/dote/doae040.

Effect of Neoadjuvant Immunotherapy Combined with Chemotherapy on Pulmonary Function and Postoperative Pulmonary Complications in Esophageal Cancer: A Retrospective Study.

Gao Y, Zhang H, Qiu Y, Bian X, Wang X, Li Y Curr Cancer Drug Targets. 2024; 24(10):1061-1070.

PMID: 38310460 DOI: 10.2174/0115680096280761231229055929.

Relationship between the severity of emphysematous change in the lung and morbidity after esophagectomy for esophageal cancer: A retrospective study on a novel strategy for risk prediction.

Horinouchi T, Yoshida N, Shiraishi S, Hara Y, Matsumoto C, Toihata T Thorac Cancer. 2023; 15(1):15-22.

PMID: 38069606 PMC: 10761611. DOI: 10.1111/1759-7714.15146.

References

Hoeppner J, Lordick F, Brunner T, Glatz T, Bronsert P, Rothling N . ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer. 2016; 16:503. PMC: 4952147. DOI: 10.1186/s12885-016-2564-y. View

Elliott J, OByrne L, Foley G, Murphy C, Doyle S, King S . Effect of neoadjuvant chemoradiation on preoperative pulmonary physiology, postoperative respiratory complications and quality of life in patients with oesophageal cancer. Br J Surg. 2019; 106(10):1341-1351. DOI: 10.1002/bjs.11218. View

Fonarow G, Hsu J . Left Ventricular Ejection Fraction: What Is "Normal"?. JACC Heart Fail. 2016; 4(6):511-3. DOI: 10.1016/j.jchf.2016.03.021. View

Asakura H, Hashimoto T, Zenda S, Harada H, Hirakawa K, Mizumoto M . Analysis of dose-volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer. Radiother Oncol. 2010; 95(2):240-4. DOI: 10.1016/j.radonc.2010.02.006. View

Mohamed Hoesein F, Zanen P, Lammers J . Lower limit of normal or FEV1/FVC < 0.70 in diagnosing COPD: an evidence-based review. Respir Med. 2011; 105(6):907-15. DOI: 10.1016/j.rmed.2011.01.008. View

Cormack O, Zaborowski A, King S, Healy L, Daly C, OFarrell N . New-onset atrial fibrillation post-surgery for esophageal and junctional cancer: incidence, management, and impact on short- and long-term outcomes. Ann Surg. 2014; 260(5):772-8. DOI: 10.1097/SLA.0000000000000960. View

Reynolds J, Preston S, ONeill B, Baeksgaard L, Griffin S, Mariette C . ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS). BMC Cancer. 2017; 17(1):401. PMC: 5457631. DOI: 10.1186/s12885-017-3386-2. View

Avendano C, Flume P, Silvestri G, King L, Reed C . Pulmonary complications after esophagectomy. Ann Thorac Surg. 2002; 73(3):922-6. DOI: 10.1016/s0003-4975(01)03584-6. View

Low D, Alderson D, Cecconello I, Chang A, Darling G, DJourno X . International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG). Ann Surg. 2015; 262(2):286-94. DOI: 10.1097/SLA.0000000000001098. View

10.

Minnella E, Awasthi R, Loiselle S, Agnihotram R, Ferri L, Carli F . Effect of Exercise and Nutrition Prehabilitation on Functional Capacity in Esophagogastric Cancer Surgery: A Randomized Clinical Trial. JAMA Surg. 2018; 153(12):1081-1089. PMC: 6583009. DOI: 10.1001/jamasurg.2018.1645. View

11.

van Hagen P, Hulshof M, van Lanschot J, Steyerberg E, van Berge Henegouwen M, Wijnhoven B . Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366(22):2074-84. DOI: 10.1056/NEJMoa1112088. View

12.

Law S, Wong K, Kwok K, Chu K, Wong J . Predictive factors for postoperative pulmonary complications and mortality after esophagectomy for cancer. Ann Surg. 2004; 240(5):791-800. PMC: 1356484. DOI: 10.1097/01.sla.0000143123.24556.1c. View

13.

Damrauer J, Stadler M, Acharyya S, Baldwin A, Couch M, Guttridge D . Chemotherapy-induced muscle wasting: association with NF-κB and cancer cachexia. Eur J Transl Myol. 2018; 28(2):7590. PMC: 6036305. DOI: 10.4081/ejtm.2018.7590. View

14.

Enright P . The six-minute walk test. Respir Care. 2003; 48(8):783-5. View

15.

Ferguson M, Durkin A . Preoperative prediction of the risk of pulmonary complications after esophagectomy for cancer. J Thorac Cardiovasc Surg. 2002; 123(4):661-9. DOI: 10.1067/mtc.2002.120350. View

16.

Klevebro F, Johnsen G, Johnson E, Viste A, Myrnas T, Szabo E . Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation. Eur J Surg Oncol. 2015; 41(7):920-6. DOI: 10.1016/j.ejso.2015.03.226. View

17.

Alexandersson von Dobeln G, Nilsson M, Adell G, Johnsen G, Hatlevoll I, Tsai J . Pulmonary function and cardiac stress test after multimodality treatment of esophageal cancer. Pract Radiat Oncol. 2016; 6(3):e53-e59. DOI: 10.1016/j.prro.2015.10.015. View

18.

Liedman B, Johnsson E, Merke C, Ruth M, Lundell L . Preoperative adjuvant radiochemotherapy may increase the risk in patients undergoing thoracoabdominal esophageal resections. Dig Surg. 2001; 18(3):169-75. DOI: 10.1159/000050125. View

19.

Kumagai K, Rouvelas I, Tsai J, Mariosa D, Klevebro F, Lindblad M . Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers. Br J Surg. 2014; 101(4):321-38. DOI: 10.1002/bjs.9418. View

20.

Richardson K, Levett D, Jack S, Grocott M . Fit for surgery? Perspectives on preoperative exercise testing and training. Br J Anaesth. 2017; 119(suppl_1):i34-i43. DOI: 10.1093/bja/aex393. View